Fluzoparide combined with apatinib mesylate in the treatment of platinum resistant recurrent ovarian cancer: A single arm, single center, prospective clinical study

被引：0
|
作者：
Sun, L. X. [1 ]
Zhao, H. W. [1 ]
机构：
[1] Shanxi Canc Hosp, Dept Med, Taiyuan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
823TiP
引用
收藏
页码：S772 / S772
页数：1
相关论文
共 50 条
  • [1] A phase 2, single arm, prospective clinical study of antitinib hydrochloride combined with letrozole in the treatment of platinum resistant recurrent ovarian cancer
    Wang, Xipeng
    Li, Jiarui
    Xing, Lingxi
    Chen, Huihui
    Wang, Yizhi
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A71 - A71
  • [2] Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
    Lan, Chun-Yan
    Wang, Yin
    Xiong, Ying
    Li, Jun-Dong
    Shen, Jing-Xian
    Li, Yan-Fang
    Zheng, Min
    Zhang, Yan-Na
    Feng, Yan-Ling
    Liu, Qing
    Huang, Hui-Qiang
    Huang, Xin
    LANCET ONCOLOGY, 2018, 19 (09): : 1239 - 1246
  • [3] Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study
    Shen, Wenbin
    Jing, Chuyu
    Tian, Wenjuan
    Zhang, Wei
    Ren, Yulan
    Shan, Boer
    Wang, Huaying
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (11) : 1764 - 1770
  • [4] Anlotinib in patients with recurrent platinum-resistant or -refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study
    Wang, H.
    Shan, B.
    Shen, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S733 - S733
  • [5] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
    Wang, Huaying
    Shen, Wenbin
    Shan, Boer
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
    Shan, Boer
    Shen, Wenbin
    Wang, Huaying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Anlotinib in patients with recurrent platinum-resistant or platinum-refractory ovarian carcinoma: A prospective, single-center, single-arm, phase II clinical trial
    Wang, Huaying
    Shan, Boer
    Tian, Wenjuan
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S23 - S23
  • [8] Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial
    Ye, Shuang
    Fu, Yi
    Liu, Shuai
    Wang, Jun
    Zhou, Lin
    Jiang, Wei
    Pei, Xuan
    Shen, Wenbin
    Sun, Min
    Shan, Boer
    Yang, Huijuan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A262 - A263
  • [9] EFFICACY AND SAFETY OF NIRAPARIB COMBINED WITH ORAL ETOPOSIDE IN PLATINUM RESISTANT/REFRACTORY RECURRENT OVARIAN CANCER: A MULTICENTRE, SINGLE ARM, PROSPECTIVE PHASE II TRIAL
    Zhou, Huimei
    Yang, Jiaxin
    Liu, Qian
    Li, Qingshui
    Zhang, Depu
    Cao, Dongyan
    Xiang, Yang
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A177 - A177
  • [10] Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study (vol 19, pg 1239, 2018)
    Lan, C-Y
    Wang, Y.
    Xiong, Y.
    LANCET ONCOLOGY, 2018, 19 (09): : E440 - E440
12345